| Name: | Imatinib Piperazine-N,N-DiOxide |
| Catalogue No. | VE006650 |
| CAS No. | 571186-93-1 |
| Molecular Formula | C29H31N7O3 |
| Molecular Weight | 525.60 |
| Status | In-stock |
| IUPAC Name | 4-[(4-Methyl-1,4-dioxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide |
| Appearance | Off-White to Pale Yellow Solid |
| Description | Imatinib Piperazine-N, N-DiOxide (CAS No: 571186-93-1) Or 4-[(4-Methyl-1,4-dioxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide, it is an impurity of imatinib, used to treat certain types of cancer such as acute lymphoblastic leukaemia, chronic myeloid leukaemia, gastrointestinal stromal tumours. |
| References | Sci-Hub | Association of the Trough, Peak/Trough Ratio of Imatinib, PyridineâN-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients | 10.3389/fonc.2020.01348. (2020). Retrieved December 9, 2021, from Hkvisa.net website: https://sci-hub.hkvisa.net/10.3389/fonc.2020.01348 |
